Molecular design, functional characterization and structural basis of a protein inhibitor against the HIV-1 pathogenicity factor Nef

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Breuer, Sebastian ^a,c   Schievink, Simone I ^b   Schulte, Antje ^a   Blankenfeldt, Wulf ^a   Fackler, Oliver T ^b   Geyer, Matthias ^a  

^a MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; NEF INHIBITOR; NEF PROTEIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LIPID MEMBRANE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN PRENYLATION; PROTEIN STRUCTURE; PROTEIN TARGETING; PROTEIN TRANSPORT; STRUCTURE ACTIVITY RELATION; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; METABOLISM;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; CELLS, CULTURED; DRUG DESIGN; HIV-1; HUMANS; MODELS, MOLECULAR; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PROTEIN BINDING;

EID: 79956336664     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020033     Document Type: Article

References (66)

1. Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, et al. (2009) Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 9: 409-417.
2. Flexner C, (2007) HIV drug development: the next 25 years. Nat Rev Drug Discov 6: 959-966.
3. Geyer M, Fackler OT, Peterlin BM, (2001) Structure-function relationships in HIV-1 Nef. EMBO Rep 2: 580-585.
4. Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, et al. (1995) Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270: 988-991.
5. Hanna Z, Kay DG, Rebai N, Guimond A, Jothy S, et al. (1998) Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 95: 163-175.
6. Kestler HW 3rd, Ringler DJ, Mori K, Panicali DL, Sehgal PK, et al. (1991) Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65: 651-662.
7. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC, (1995) Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 332: 228-232.
8. Fackler OT, Moris A, Tibroni N, Giese SI, Glass B, et al. (2006) Functional characterization of HIV-1 Nef mutants in the context of viral infection. Virology 351: 322-339.
9. Kirchhoff F, Schindler M, Specht A, Arhel N, Munch J, (2008) Role of Nef in primate lentiviral immunopathogenesis. Cell Mol Life Sci 65: 2621-2636.
10. Roeth JF, Collins KL, (2006) Human immunodeficiency virus type 1 Nef: adapting to intracellular trafficking pathways. Microbiol Mol Biol Rev 70: 548-563.
11. Stolp B, Reichman-Fried M, Abraham L, Pan X, Giese SI, et al. (2009) HIV-1 Nef interferes with host cell motility by deregulation of Cofilin. Cell Host Microbe 6: 174-186.
12. Fackler OT, Alcover A, Schwartz O, (2007) Modulation of the immunological synapse: a key to HIV-1 pathogenesis? Nat Rev Immunol 7: 310-317.
13. Schindler M, Münch J, Kutsch O, Li H, Santiago ML, et al. (2006) Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 125: 1055-1067.
14. Jere A, Fujita M, Adachi A, Nomaguchi M, (2010) Role of HIV-1 Nef protein for virus replication in vitro. Microbes Infect 12: 65-70.
15. Haller C, Tibroni N, Rudolph JM, Grosse R, Fackler OT, (2011) Nef does not inhibit F-actin remodelling and HIV-1 cell-cell transmission at the T lymphocyte virological synapse. Eur J Cell Biol in press, doi:10.1016/j.ejcb.2010.09.010.
16. Betzi S, Restouin A, Opi S, Arold ST, Parrot I, et al. (2007) Protein protein interaction inhibition (2P2I) combining high throughput and virtual screening: Application to the HIV-1 Nef protein. Proc Natl Acad Sci U S A 104: 19256-19261.
17. Olszewski A, Sato K, Aron ZD, Cohen F, Harris A, et al. (2004) Guanidine alkaloid analogs as inhibitors of HIV-1 Nef interactions with p53, actin, and p56lck. Proc Natl Acad Sci U S A 101: 14079-14084.
18. Emert-Sedlak L, Kodama T, Lerner EC, Dai W, Foster C, et al. (2009) Chemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compounds. ACS Chem Biol 4: 939-947.
19. Dikeakos JD, Atkins KM, Thomas L, Emert-Sedlak L, Byeon IJ, et al. (2010) Small molecule inhibition of HIV-1-induced MHC-I down-regulation identifies a temporally regulated switch in Nef action. Mol Biol Cell 21: 3279-3292.
20. Geyer M, Peterlin BM, (2001) Domain assembly, surface accessibility and sequence conservation in full length HIV-1 Nef. FEBS Lett 496: 91-95.
21. Mangasarian A, Piguet V, Wang JK, Chen YL, Trono D, (1999) Nef-induced CD4 and major histocompatibility complex class I (MHC-I) down-regulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking. J Virol 73: 1964-1973.
22. Michel N, Allespach I, Venzke S, Fackler OT, Keppler OT, (2005) The Nef protein of human immunodeficiency virus establishes superinfection immunity by a dual strategy to downregulate cell-surface CCR5 and CD4. Curr Biol 15: 714-723.
23. Hiipakka M, Huotari P, Manninen A, Renkema GH, Saksela K, (2001) Inhibition of cellular functions of HIV-1 Nef by artificial SH3 domains. Virology 286: 152-159.
24. Craig HM, Pandori MW, Guatelli JC, (1998) Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 down-regulation and optimal viral infectivity. Proc Natl Acad Sci U S A 95: 11229-11234.
25. Geyer M, Yu H, Mandic R, Linnemann T, Zheng YH, et al. (2002) Subunit H of the V-ATPase binds to the medium chain of adaptor protein complex 2 and connects Nef to the endocytic machinery. J Biol Chem 277: 28521-28529.
26. Grzesiek S, Stahl SJ, Wingfield PT, Bax A, (1996) The CD4 determinant for downregulation by HIV-1 Nef directly binds to Nef. Mapping of the Nef binding surface by NMR. Biochemistry 35: 10256-10261.
27. Lee CH, Leung B, Lemmon MA, Zheng J, Cowburn D, et al. (1995) A single amino acid in the SH3 domain of Hck determines its high affinity and specificity in binding to HIV-1 Nef protein. EMBO J 14: 5006-5015.
28. Hiipakka M, Poikonen K, Saksela K, (1999) SH3 domains with high affinity and engineered ligand specificities targeted to HIV-1 Nef. J Mol Biol 293: 1097-1106.
29. Geyer M, Fackler OT, Peterlin BM, (2002) Subunit H of the V-ATPase involved in endocytosis shows homology to beta-adaptins. Mol Biol Cell 13: 2045-2056.
30. Misra S, Puertollano R, Kato Y, Bonifacino JS, Hurley JH, (2002) Structural basis for acidic-cluster-dileucine sorting-signal recognition by VHS domains. Nature 415: 933-937.
31. Shiba T, Takatsu H, Nogi T, Matsugaki N, Kawasaki M, et al. (2002) Structural basis for recognition of acidic-cluster dileucine sequence by GGA1. Nature 415: 937-941.
32. Arold S, O'Brien R, Franken P, Strub MP, Hoh F, et al. (1998) RT loop flexibility enhances the specificity of Src family SH3 domains for HIV-1 Nef. Biochemistry 37: 14683-14691.
33. Kim PW, Sun ZY, Blacklow SC, Wagner G, Eck MJ, (2003) A zinc clasp structure tethers Lck to T cell coreceptors CD4 and CD8. Science 301: 1725-1728.
34. Gerlach H, Laumann V, Martens S, Becker CF, Goody RS, et al. (2010) HIV-1 Nef membrane association depends on charge, curvature, composition and sequence. Nat Chem Biol 6: 46-53.
35. Aiken C, Trono D, (1995) Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol 69: 5048-5056.
36. Lee CH, Saksela K, Mirza UA, Chait BT, Kuriyan J, (1996) Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain. Cell 85: 931-942.
37. Arold S, Franken P, Strub MP, Hoh F, Benichou S, et al. (1997) The crystal structure of HIV-1 Nef protein bound to the Fyn kinase SH3 domain suggests a role for this complex in altered T cell receptor signaling. Structure 5: 1361-1372.
38. Piguet V, Wan L, Borel C, Mangasarian A, Demaurex N, et al. (2000) HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes. Nat Cell Biol 2: 163-167.
39. Arkin MR, Wells JA, (2004) Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 3: 301-317.
40. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW, (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science 274: 1531-1534.
41. Sauter D, Specht A, Kirchhoff F, (2010) Tetherin: holding on and letting go. Cell 141: 392-398.
42. Yamamoto T, Samri A, Marcelin AG, Mitsuki YY, Vincent C, et al. (2009) Effect of lentivirus encoding HIV-1 Nef-U3 shRNA on the function of HIV-specific memory CD4(+) T cells in patients with chronic HIV-1 infection. AIDS 23: 2265-2275.
43. Christ F, Voet A, Marchand A, Nicolet S, Desimmie BA, et al. (2010) Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 6: 442-448.
44. Goffinet C, Allespach I, Keppler OT, (2007) HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription. Proc Natl Acad Sci USA 104: 1015-1020.
45. Sun Z, Denton PW, Estes JD, Othieno FA, Wei BL, et al. (2007) Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med 204: 705-714.
46. Baenziger S, Tussiwand R, Schlaepfer E, Mazzucchelli L, Heikenwalder M, et al. (2006) Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-γc-/- mice. Proc Natl Acad Sci USA 103: 15951-15956.
47. Eckert DM, Malashkevich VN, Hong LH, Carr PA, Kim PS, (1999) Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99: 103-115.
48. Root MJ, Kay MS, Kim PS, (2001) Protein design of an HIV-1 entry inhibitor. Science 291: 884-888.
49. Bartonova V, Igonet S, Sticht J, Glass B, Habermann A, et al. (2008) Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein. J Biol Chem 283: 32024-32033.
50. Sticht J, Humbert M, Findlow S, Bodem J, Müller B, et al. (2005) A peptide inhibitor of HIV-1 assembly in vitro. Nat Struct Mol Biol 12: 671-677.
51. Ternois F, Sticht J, Duquerroy S, Krausslich HG, Rey FA, (2005) The HIV-1 capsid protein C-terminal domain in complex with a virus assembly inhibitor. Nat Struct Mol Biol 12: 678-682.
52. Zhang H, Zhao Q, Bhattacharya S, Waheed AA, Tong X, et al. (2008) A cell-penetrating helical peptide as a potential HIV-1 inhibitor. J Mol Biol 378: 565-580.
53. Breuer S, Gerlach H, Kolaric B, Urbanke C, Opitz N, et al. (2006) Biochemical indication for myristoylation-dependent conformational changes in HIV-1 Nef. Biochemistry 45: 2339-2349.
54. Szilluweit R, Boll A, Lukowski S, Gerlach H, Fackler OT, et al. (2009) HIV-1 Nef perturbs artificial membranes: investigation of the contribution of the myristoyl anchor. Biophys J 96: 3242-3250.
55. Vollmuth F, Geyer M, (2010) Interaction of propionylated and butyrylated histone H3 lysine marks with Brd4 bromodomains. Angew Chem Int Ed 49: 6768-6772.
56. Kabsch W, (2010) Xds. Acta Crystallogr D Biol Crystallogr 66: 125-132.
57. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658-674.
58. Emsley P, Cowtan K, (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
59. Murshudov GN, Vagin AA, Dodson EJ, (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240-255.
60. Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution.Acta Crystallogr. D Biol Crystallogr 66: 213-221.
61. Grzesiek S, Bax A, Clore GM, Gronenborn AM, Hu JS, et al. (1996) The solution structure of HIV-1 Nef reveals an unexpected fold and permits delineation of the binding surface for the SH3 domain of Hck tyrosine protein kinase. Nat Struct Biol 3: 340-345.
62. Grzesiek S, Bax A, Hu JS, Kaufman J, Palmer I, et al. (1997) Refined solution structure and backbone dynamics of HIV-1 Nef. Protein Sci 6: 1248-1263.
63. Brügger B, Krautkrämer E, Tibroni N, Munte CE, Rauch S, et al. (2007) Human immunodeficiency virus type 1 Nef protein modulates the lipid composition of virions and host cell membrane microdomains. Retrovirology 4: 70.
64. Neidig KP, Geyer M, Görler A, Antz C, Saffrich R, et al. (1995) AURELIA, a program for computer-aided analysis of multidimensional NMR spectra. J Biomol NMR 6: 255-270 (1995).
65. Keppler OT, Allespach I, Schüller L, Fenard D, Greene WC, et al. (2005) Rodent cells support key functions of the human immunodeficiency virus type 1 pathogenicity factor Nef. J Virol 79: 1655-1665.
66. Homann S, Tibroni N, Baumann I, Sertel S, Keppler OT, et al. (2009) Determinants in HIV-1 Nef for enhancement of virus replication and depletion of CD4+ T lymphocytes in human lymphoid tissue ex vivo. Retrovirology 6: 6.